The Swedish national healthcare region of Östergötland signs central agreement with Airsonett for treatment with TLA for patients with severe allergic asthma
The expert group for respiratory organs in the region of Östergötland has since 2016 recommended TLA as a complementary treatment for adults and children over 6 with severe asthma, who, despite optimal medication, have uncontrolled asthma. However, the prescription was previously limited to the allergy center in Linköping. With the new central agreement, it is possible to prescribe TLA in the whole healthcare region of Östergötland, which will attribute to fair and even care throughout the entire region.
“The agreement with the region of Östergötland is further proof of the increased acceptance of the treatment with Airsonett TLA in healthcare in Sweden. We expect that 2-3 larger regions in Sweden will sign similar agreements with us during autumn”, says Anders Due-Boje, CEO Airsonett AB.
About severe, uncontrolled asthma
Patients with severe, uncontrolled asthma treated according to Global Initiative for Asthma (GINA) step 4/5 account for approximately 3% of all patients with persistent asthma, according to recent population-based studies using administrative and prescribed databases, but account for a much larger share of asthma-related healthcare resource use and costs. Treatment alternatives for such patients include high-dose inhaled corticosteroids (ICS) and long-acting β2-antagonists (LABAs) and/or systematic corticosteroids. During the last decade, several new drugs for the treatment of severe asthma have been developed, and some of these drugs, such as anti-immunoglobulin E and anti-interleukin 5 have been included in Step 5 in the latest GINA recommendations. The costs for treatment with these biologics are however very high. Temperature-controlled laminar airflow (TLA) is a relatively new treatment for patients with severe, uncontrolled asthma. The use of TLA has shown cost-effectiveness according to National Institute for Health and Care Excellence (NICE) standards and the Swedish Dental and Pharmaceutical Benefits Agency, TLV, a central government agency whose remit is to determine whether a pharmaceutical product, medical device or dental care procedure shall be subsidized by the state.
For more information:
Anders Due-Boje, CEO, Airsonett AB
Phone: +46 70 526 03 00
E-mail: anders.due-boje@airsonett.eu
About Airsonett
Airsonett® är ett svenskt medicintekniskt företag som är ledande inom icke-farmakologisk behandling av patienter med allergisk svår, okontrollerad astma och eksem. Airsonett® Air4 är en icke-invasiv medicinsk utrustning för hembehandling baserad på den patenterade tekniken Temperatur-reglerat laminärt luftflöde (TLA). Behandling med Airsonett® Air4 medför drastisk minskning av allergener och andra luftburna partiklar i patientens andningszon under vila och sömn. Airsonett® Air4 rekommenderas av Socialstyrelsen och Barnläkarföreningen samt ingår sedan 2015 i Läkemedelsverkets riktlinjer för astmabehandling. Airsonett® Air4 är en CE-märkt medicinteknisk utrustning, Klass 1, avsedd att användas för lindring av symtom vid allergiska sjukdomar såsom allergisk astma och eksem. Den följer relevanta EU-direktiv gällande utformning, funktion, säkerhet, hälsokrav och har genomgått rigorös klinisk forskning så väl som hälsoekonomiska analyser. Airsonett® Air4 innehar ett 510(k) godkännande, klass II, från FDA. Bolagets huvudägare är SEB Venture Capital, Industrifonden och Magnus Lundberg. För ytterligare information, besök www.airsonett.se
Powered by Notified